Article Type
Original Study
Abstract
Aim The aim of this study was to assess serum matrix metalloproteinase 3 (MMP-3) level in patients of systemic lupus erythematosus (SLE) and its relation to various clinical and laboratory findings. Patients and methods The study involved 40 female patients with SLE as a study group and 20 sex-matched and age-matched healthy individuals as a control group. All patients were subjected to thorough clinical examinations and laboratory investigations. Disease activity was assessed using SLE Disease Activity Index, as well as Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Serum level of MMP-3 was assessed using enzyme-linked immunosorbent assay technique. Patients who showed clinical manifestations of neuropsychiatric lupus were subjected to brain MRI. Results The mean serum MMP-3 was significantly higher in patients with SLE than controls (24.93 ± 21.67 vs. 6.98 ± 1.85,P < 0.001) and in patients with nephritis or cerebritis than patients presented with other clinical features (P = 0.009 and 0.018, respectively). Serum MMP-3 was significantly positively correlated with SLE Disease Activity Index (P = 0.001) and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (P = 0.02) as well as laboratory markers of disease activity such as anti-double-stranded DNA antibodies and erythrocyte sedimentation rate (P < 0.001). Patients with neuropsychiatric lupus showed normal MRI brain findings, except one 21-year-old female patient who presented with psychosis showed atrophic changes. MMP-3 at cutoff of at least 26.7 μg/ml can significantly predict patients with nephritis with sensitivity of 77.8% and specificity of 95.5%; area under the curve was 0.842. Conclusion MMP-3 was reported to be higher in patients with SLE than controls and patients who presented with either nephritis or neuropsychiatric symptoms showed elevated level of MMP-3 than patients presented with other clinical manifestations. In addition to its proven role in development of lupus nephritis, this study highlighted the possible role of MMP-3 in neuropsychiatric disease.
Keywords
Matrix metalloproteinase 3, nephritis, neuropsychiatric lupus, systemic lupus erythematosus
Recommended Citation
Amer, Eman R.; Elshabacy, Fatema A.; Elhameed Tabl, Hala A.; Ebrahim, Lobna Y.; and M. Mostafa, Taghreed F.
(2019)
"Serum level of matrix metalloproteinase 3 (stromelysin 1) in patients with systemic lupus erythematosus: relation to clinical nephritis and neuropsychiatric manifestations,"
Journal of Medicine in Scientific Research: Vol. 2:
Iss.
2, Article 1.
DOI: https://doi.org/10.4103/JMISR.JMISR_27_19
